The Ability and Tasks of Pharmacovigilance and Adverse Drug Events in India a Global Scenario

Prachi Gurudiwan[1], Poorti Sharma[2]

[1]*Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.*
[2]*Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.*

KEYWORDS

Health care, Pharmacovigilance, Medicine.

ABSTRACT

Clinical trials are the first stage of pharmacovigilance, which continues until the medication is put on the market. Social media's introduction provides access to healthcare data that hasn't been vetted by conventional techniques of data collection. Enhancing clinical and scientific understanding of pharmacovigilance could be greatly aided by using natural language processing tools to retrieve patient reports of adverse medication occurrences from social media. Signal detection encompasses all side effects connected to a medication. The primary goal of the study is to extract information from the FAERS data, which includes both organized and unstructured patient information on prior adverse drug reactions. The study examines how the side effects of acetaminophen and ibuprofen are extracted and managed using the proper techniques.

1. Introduction

Medical science plays a significant role in maintaining health and preventing and treating disease; however, there are side effects associated with drug use known as adverse drug reactions (ADRs), which are defined as "harmful side effects due to use of single medicine or multiple drugs [1]." Adverse drug events (ADEs) are another kind of adverse pharmaceutical effects. ADR reporting is crucial for monitoring medications that may react differently in individuals with various conditions, such as diabetes, heart problems [7], etc., according to the World Health Organisation. ADRs frequently result from pre-existing conditions in the patient, and unintentional drug introductions can introduce new issues [2]. In the United States, it is estimated that over a million people visit hospital emergency rooms annually due to bad medication reactions. With an estimated $136 billion in yearly costs in the United States, ADRs pose a significant financial strain on the country's economy. a harmful, unintentional reaction that happens at dosages often employed in humans for disease prophylaxis, diagnosis, treatment, or alteration of physiological function. Linking preclinical data from hospitals with information on human safety is the newest trend in PhV (Mei, Liu et al., 2012). Worldwide, pharmacovigilance is a component of healthcare systems [3]. The WHO oversees pharmacovigilance initiatives and offers assistance with technical aspects of ADR reporting. Although pharmacovigilance systems are well-established in many countries, the true rate of adverse drug reactions is far higher than reported. ADR underreporting is a serious issue, as is the calibre of reports. Pharmacovigilance's main goals are patient safety, safe drug usage, and, in the end, maintaining public health. International organisations and national regulators should encourage the public and medical professionals to report more ADRs in order to accomplish this goal [11]. The rest of the paper is organized as follows: Section 2 provides the classification scheme for the survey; Section 3 provides an overview of proposed architecture. Section 4 provides a summary and comparison of the results of the various papers discussed in this taxonomy. Finally, Section 5 concludes the paper.

2. Related Works

The pharmacological science of identifying and averting both immediate and long-term drug side effects is known as pharmacovigilance. In reaction to the thalidomide tragedy, the World Health Organisation (WHO) created the Pharmacovigilance Programme for International Drug Monitoring [5]. India became a member of the WHO's Uppsala, Sweden-based adverse drug reaction monitoring program. Vigilant monitoring and reporting could prevent negative impacts. Under the auspices of the Ministry of Health and Family Welfare, the Central Drugs Standard Control Organisation (CDSCO) launched the pharmacovigilance initiative in developing nations in November 2004. The WHO paper titled Safety monitoring of pharmaceutical goods guidelines for setting up and administering a pharmacovigilance centre [6] contains the principles that serve as its foundation. The goal was to keep an eye on adverse drug reactions (ADRs), report through the pharmacovigilance network hierarchy,

and share the information with the world's medical community via the WHO-Uppsala Monitoring Centre. Under the Pharmacovigilance Program of India, adverse drug reaction monitoring centres (AMCs) are essential to the gathering and tracking of patient complaints of adverse drug reactions (ADRs). Individuals who suffer from liver illness and chronic kidney disease (CKD) are more vulnerable to drug-related side effects [12]. Any negative events should be documented and these individuals should be continuously watched for. Consequently, encouraging the reporting of adverse drug reactions (ADRs) will aid in the generation of data unique to the Indian population and will advance patient safety [4]. This will also assist in changing the course of treatment for patients because early detection of ADRs will lower morbidity and mortality in patients.

3. Methodology

The FAERS database and the standard WHO medication is used for the data mapping. Drugs like ibuprofen and paracetamol were examined in order to obtain data from the FAERS dataset. The same gathers data from all across the world and is unstructured. After extraction, the data is cleaned, and any missing values are properly handled. The entire procedure is executed with OpenVigil 2. A profile of adverse events and a disproportionality study between medications have been created. The use of effective data mining algorithms, including Enhanced ID3 and C4.5, is the primary procedure. Machine learning is the study of computer algorithms that automatically get better with use. Machine learning is used in a variety of applications, such as information filtering systems that automatically learn users' interests and data mining programs that find general principles in massive data sets. Through the application of machine learning, systems can be developed that are more effective and efficient. [8].



Figure 1. Framework of Proposed Method

For acute pain, paracetamol is frequently used with a non-steroidal anti-inflammatory medication. The side effects are gathered from patients worldwide and kept in a database for the widely used medication acetaminophen, also known as paracetamol. Due to the lengthy and intricate process involved in manufacturing drugs, adverse events pose a significant challenge to the pharmaceutical sector. Numerous phases of clinical trials and surveillance precede numerous stages of drug discovery throughout the process. The FAERS database is searched for the data needed for the study, and any missing values are properly handled. Disproportionality analyses of adverse events are conducted, and a comparison of the adverse events for acetaminophen and ibuprofen is discovered. Large datasets can be mined for intriguing patterns using data mining methods [9]. The two primary uses of the algorithm in pharmacology are the identification of medications that have novel effects and the appropriateness of drug administration (i.e., certain pharmaceuticals should not be used for extended periods of time due to side effects or allergies from using other drugs). Pharmacovigilance is the practice of identifying

adverse events from huge real-time datasets by means of data mining algorithms. Drug safety can be determined by assessing adverse occurrences, as different drug kinds have varying side effects [10].

4. Results And Discussion

The analysis tool used in this paper for Pharmacovigilance is OpenVigil 2. There have been 559855 adverse effect cases for paracetamol with distinct class numbers of 8458 documented. Table 6.2 lists 150 unfavourable events and the quantity of occurrences for each. On the basis of paracetamol adverse events retrieved from FAERS, a disproportionality analysis was conducted. Figure 2 displays a plot of PRR and chi-square, and Figure 3 displays a plot of ROR for paracetamol in relation to the possibility of an adverse event.



Figure 2. The plot of chi-square and PRR for Acetaminophen



Figure 3. Plot of ROR for Acetaminophen

Ibuprofen is another often used substitute for acetaminophen. A comparative analysis of these two medications is presented in Figure 4. It is evident from the graph that ibuprofen has fewer side effects than paracetamol.



Figure 4. Comparison of adverse effects of Ibuprofen and Acetaminophen



Figure 5. Percentage of a drug interaction of Acetaminophen and Ibuprofen

Acetaminophen and Ibuprofen medication interaction percentage is displayed in Figure 5. Data is extracted and analysed as it is found over time by browsing ADR's publicly accessible web database. Given their widespread use as pain relievers, ibuprofen and paracetamol have a wealth of data from a variety of age groups and illnesses. The ability to analyse drug-drug interactions was made possible by data on the combination of this medication with other medications used by individuals with chronic illnesses. There was no proof that the medications' incidence of mild or significant harm varied from one another or from a placebo (17 safety trials; 1820 children). Both prior to and 30 minutes following administration, the patient's temperature was taken. After taking the medication for the next eight hours, the patient's temperature was taken every hour. Patients who had taken medications were asked to report any further side effects of the drug after they were discharged and were monitored for adverse drug reactions (ADRs) for a week. When compared to acetaminophen, ibuprofen was found to deliver a significant drop in temperature.

5. Conclusions

Acetaminophen is a medication that is frequently used to treat fever and pain. Adverse events resulting from pharmaceuticals and medication errors are gathered globally and kept in a database known as FAERS. The acetaminophen-related adverse reaction is taken out of this database and preprocessed. The research of Acetaminophen and Ibuprofen adverse events, the discovery of medications that produce new effects, and the appropriateness of drug use led to the disproportionality analysis. After comparing the safety profiles of acetaminophen and ibuprofen, it was shown that ibuprofen had far fewer side effects. Analysis was also done on the negative effects of using acetaminophen and ibuprofen.

References

[1] Palaian, Subish. "Pharmacovigilance practices and activities: Issues, challenges, and future direction." In *Social and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries*, pp. 145-162. Academic Press, 2018.

[2] Mansuri, Asra, and Tabrez Uz Zaman. "Pharmacovigilance: A Necessary Tool for Drug Safety Monitoring Globally." Journal of Drug Delivery and Therapeutics 14, no. 4 (2024): 96-103.

[3] Fernandes, Swapnil Dylan, Narayanan V. Anoop, Lovely Joylen Castelino, and R. Narayana Charyulu. "A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials." Research in Social and Administrative Pharmacy 15, no. 1 (2019): 109-113.

[4] Sonya, A., & Kavitha, G. (2022). A Data Integrity and Security Approach for Health Care Data in Cloud Environment. Journal of Internet Services and Information Security, 12(4), 246-256.

[5] Shukla, Shalini, Priyanka Sharma, Priya Gupta, Shikha Pandey, Reshu Agrawal, Deepak Rathour, Dharmendra Kumar Kewat et al. "Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India." Current Drug Safety 19, no. 2 (2024): 172-190.

[6] Dutta, Avisek, Anupam Banerjee, Shrobona Basu, and Sunil Chaudhry. "Analysis of under-reporting of adverse drug reaction: Scenario in India and neighbouring countries." IP Int J Compr Adv Pharmacol 5, no. 3 (2020): 118-124.

[7] Sofiene, M., Souhaila, B., & Souhir, C. (2024). Machine Learning for Early Diabetes Detection and Diagnosis. Journal of Wireless Mobile Networks, Ubiquitous Computing, and Dependable Applications (JoWUA), 15(1), 216-230.

[8] Mohiuddin, A. K. "Pharmacovigilance: Present Scenario and Future Goals." Indian Journal of Pharmacy Practice 12, no. 1 (2019).

[9] Abadi, S., Huda, M., Teh, K.S.M., Haroon, Z., Ripin, M.N., Hehsan, A., Sarip, S., Hehsan, M.R., Amrullah, M., Maseleno, A. Hazard level of vehicle smoke by fuzzy multiple attribute decision making with simple additive weighting method (2018) International Journal of Pharmaceutical Research, 10 (4), pp. 58-67. DOI: 10.31838/ijpr/2018.10.04.010

[10] Zehravi, Mehrukh, Mudasir Maqbool, and Irfat Ara. "An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India." The Indian Journal of Nutrition and Dietetics 58, no. 3 (2021): 408-18.

[11] Kalaiselvan, V., Sushma Srivastava, Abhishank Singh, and S. K. Gupta. "Pharmacovigilance in India: present scenario and future challenges." Drug safety 42 (2019): 339-346.

[12] Jain, Sandhya, Dr Vikas Jain, and Radha Sharma. "Pharmacovigilance system and the future challengesin India-A Perspective." International Journal of Pharmacy Research & Technology (IJPRT) 8, no. 2 (2018): 27-31.

[13] Mulchandani, Rubina, and Ashish Kumar Kakkar. "Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions." International Journal of Risk & Safety in Medicine 30, no. 1 (2019): 33-44.